Sixty percent of the patients (12 out of 20) in their study had CBLs that expressed CD34, CD38, CD184, CD31, CD50, and the same immunoglobulin light chain as the patients’ known myeloma cells. This evidence concerns the gene CD38 and plasma cell myeloma.